Akers stock: buy or sell?
December 6th, 2019
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally.
Should I buy Akers stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to choose your own trading plan that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Akers Biosciences stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Akers stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for AKER stock for the last 30 days.
Akers stock analysis
Akers shares plunged -6.01% to $2.97 today.
Shares of Akers closed today at $2.97 and plunged a bloodcurdling -6.01%. Since price and SMA50d lines crossed down on September, AKER fell $-7.85 per share (-72.55%).
After boosting an extraordinary 9.35% in a week last week, Akers Biosciences closed this week at $2.97 and plummed a frightening -61.43%.
Akers Biosciences is sliding further to find new supports after falling under the support. Since late September, when AKER stock price broke down the 20-weeks moving avarage line, it slid $-8.96 per share (-75.10%).
Akers stock price history
Akers stock went public on January 23rd, 2014 with a price of $1,086.721. Since then, AKER stock sliced a -99.70%, with a yearly average of -19.90%.
1: Adjusted price after possible price splits or reverse-splits.
Akers stock historical price chart
AKER stock reached 52-week highs on January at $36.96, and all-time highs 2014-01-23 with a price of 1094.4.
Akers stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' AKER stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not found any price prediction for Akers stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last April, when Akers presented its last earnings report, it . As soon as we get its actual EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Akers annual turnover plummed a scary -50.35% to $1.67 M USD from $3.35 marked in 2017. When comparing 2018 vs 2017, likewise, profit margin (that is, the net income divided by revenues) plummed a -431.79% to -651.37%.
|2012||$1.52 M||-||$-2.45 M-161.2%||-|
|2013||$3.58 M||135.53%||$-1.53 M-42.7%||-37.55%|
|2014||$4.43 M||23.66%||$-3.13 M-70.6%||104.39%|
|2015||$2.12 M||-52.23%||$-9.31 M-440.3%||197.77%|
|2016||$2.96 M||39.99%||$-3.30 M-111.6%||-64.52%|
|2017||$3.35 M||13.30%||$-7.37 M-219.6%||122.98%|
|2018||$1.67 M||-50.35%||$-10.85 M-651.4%||47.28%|
Quarterly financial resultsAkers reported $0.28 million in revenues for 2018-Q4, a -49.85% less compared to previous quarter. Reported quarter earnings marked $-3.84 million with a profit margin of -1,373.50%. Profit margin collapsed a -819.92% compared to previous quarter when profit margin was -553.58%. When comparing revenues to same quarter last year, Akers Biosciences sales marked a frightening slide and plunged a -70.24%.
|2017-Q1||$0.67 M||-||$-1.35 M-202.3%||-|
|2017-Q2||$1.07 M||60.36%||$-0.82 M-76.4%||-39.41%|
|2017-Q3||$0.68 M||-36.84%||$-1.18 M-174.3%||43.96%|
|2017-Q4||$0.94 M||38.91%||$-4.02 M-428.4%||241.48%|
|2018-Q1||$0.30 M||-67.78%||$-1.86 M-614.9%||-53.75%|
|2018-Q2||$0.53 M||74.10%||$-2.07 M-392.6%||11.15%|
|2018-Q3||$0.56 M||5.79%||$-3.08 M-553.6%||49.17%|
|2018-Q4||$0.28 M||-49.85%||$-3.84 M-1373.5%||24.44%|
Akers ownershipWhen you are planning to invest in a stock, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Akers, 0.23% of all outstanding shares are owned by its staff.
In case of Akers Biosciences stock, 8.40% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AKER stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$1.5 M|
|Total shares||0.5 M|
|Float shares||0.5 M|
|- Institutional holdings (%)||8.4%|
|- Insider holdings (%)||0.2%|
|Shares in short selling||0.0%|
|Friday, December 6th, 2019|
|Day range||$2.75 - $3.08|
|Average true range||$1.05|
|50d mov avg||$8.47|
|100d mov avg||$9.62|
|200d mov avg||$13.81|
Akers performanceTo measure stock performance is always good to benchmark with competitors or related stocks. We picked as the bechmarking frame for Akers stock.